Effect of Lactoferrin on Polio Seroconversion
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04432935|
Recruitment Status : Recruiting
First Posted : June 16, 2020
Last Update Posted : April 19, 2022
|Condition or disease||Intervention/treatment||Phase|
|Poliomyelitis||Dietary Supplement: Bovine Lactoferrin Other: Placebo Glucon D||Not Applicable|
Lactoferrin was first discovered in bovine milk which was later isolated in human milk as the second most abundant protein; with high levels found in colostrum. Evidence suggests that Lactoferrin enhances a child's immunity against gastrointestinal infections by inhibiting the growth of bacteria through iron deprivation and by preventing attachment of the virus to the intestinal cells thus children become less susceptible to virus replication in the gut. Investigations of enhanced efficacy of the BCG (Bacillus Calmette-Guérin) vaccine after administration of Lactoferrin showed promising results. The use of bovine Lactoferrin in children is generally recognized as safe by the US Food and Drug Administration. Its anti-infective properties creates a new window of opportunity to assess its effects on the level of seroconversion following poliovirus vaccination in children.
This is a double-blinded two arm randomized placebo-controlled trial. A total of 377 neonates will be enrolled in each group (754 neonates in both groups). Females ages 18-45 years in their last trimester of pregnancy in Karachi, Pakistan will be recruited for the study by the study team and consent will be obtained. Participants will be newborns (on day 1 of birth) who will be followed through 6 months of age. Newborns who fulfill the inclusion criteria will be randomly assigned to the control or intervention group in 1:1 ratio on the first day of birth. Intervention group will receive a daily bovine lactoferrin supplementation whereas Control group will receive a daily placebo supplementation along with breast milk from day 0 of birth to 6 weeks of life. Newborns will be followed up daily during the course of the hospital stay.
After discharge from the hospital, mothers will be provided with a week's supply of lactoferrin or placebo along with instructions on how and when to administer it to the baby. Newborns will be followed up weekly. Compliance will be assessed by counting the used sachets of lactoferrin or placebo because mothers will be instructed to keep the empty sachets in a dedicated container issued by study staff. Mothers will be strictly advised to administer all vaccinations according to the routine immunization schedule. For both groups, a blood sample will be collected in the hospital and containers will be given to the mother for collections of stool for the newborn.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||754 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||
Bovine lactoferrin (bLF) will be administered (300mg) from day 0 of birth to 6 weeks of life with a single daily dose mixed with milk (preferentially breast milk otherwise premature formula milk).
Placebo will be administered from day 0 of birth to 6 weeks of life. (Placebo will be physically identical to the bLF mixed with breast milk or premature formula milk).
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Masking Description:||Randomization will be carried out by Data management unit and all investigators /dispensers and participants will be masked to the randomization.|
|Official Title:||Effect of Bovine Lactoferrin on Seroconversion Following Polio Vaccine Administration in Children: A Randomized Control Trial|
|Actual Study Start Date :||October 1, 2020|
|Estimated Primary Completion Date :||June 30, 2022|
|Estimated Study Completion Date :||June 30, 2022|
Experimental: Bovine Lactoferrin
Intervention group will receive bovine lactoferrin supplementation daily once a day from day 0 of birth to 6 weeks of life.
Dietary Supplement: Bovine Lactoferrin
Lactoferrin is a nutritional supplement which was first discovered in bovine milk which was later isolated in human milk as the second most abundant protein; with high levels found in colostrum. The use of bovine Lactoferrin in children is generally recognized as safe by the US Food and Drug Administration.
Placebo Comparator: Glucon D
Control group will receive Glucon-D supplementation daily once a day from day 0 of birth to 6 weeks of life.
Other: Placebo Glucon D
This group will be given 100mg Glucon-D (99.4% glucose) which will be similar in shape, color to the bLF.
- Assessment of humoral immunity by seroconversion [ Time Frame: 10 weeks ]Presence of detectable antibodies to poliovirus types 1 and 3 in serum) after receipt of two doses of OPV
- Comparison of humoral immunity represented by seroconversion [ Time Frame: 18 weeks ]Presence of detectable antibodies to poliovirus types 1, 2 and 3 in serum) after completion of the routine immunization doses/schedule
- Comparison of intestinal immunity represented by shedding of poliovirus types 1 and 3 [ Time Frame: 19 weeks ]If lactoferrin is effective in improving intestinal immunity, shedding is expected to be lower in the lactoferrin receiving group.
- Comparison of duration of shedding among the two study arms [ Time Frame: 20 and 22 weeks ]Represented by shedding at 20 weeks of age and at 22 weeks of age after the challenge dose of bOPV administered
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04432935
|Contact: Muhammad Atif Habib, MBBS, PhD||+922134829538 ext firstname.lastname@example.org|
|Contact: Shanila Nooruddin, MBBS, MS||+922134829538 ext email@example.com|
|Principal Investigator:||Sajid Soofi, MBBS, FCPS||Aga Khan University|